ArticleMolecular medicine reports2019
MicroRNA‑363‑3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Palmatine inhibits colorectal cancer proliferation and metastasis by regulating miR-363-3p/AURKA axis.Human cell · 2025Article
- Role of microRNA-363 during tumor progression and invasion.Journal of physiology and biochemistry · 2024Review
- MicroRNA-363-3p inhibits colorectal cancer progression by targeting interferon-induced transmembrane protein 1.World journal of gastrointestinal oncology · 2023Article
- MiR-363 restrain the proliferation, migration and invasion of colorectal carcinoma cell by targeting E2F3.Journal of Cancer · 2023Article
- MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.Journal of clinical laboratory analysis · 2022Article
- Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis.Molecular medicine reports · 2021Article
- High Mobility Group A (HMGA): Chromatin Nodes Controlled by a Knotty miRNA Network.International journal of molecular sciences · 2020Review
- LncRNA FEZF1-AS1 Modulates Cancer Stem Cell Properties of Human Gastric Cancer Through miR-363-3p/HMGA2.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of microRNAs (miRNAs) in cancer development has been widely recognized in recent decades. In the present study, the function and mechanism of miRNA‑363‑3p (miR‑363‑3p), formerly characterized as a tumor suppressor, in the hepatocarcinogenesis of liver cancer cells was investigated. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was applied to detect the expression of miR‑363‑3p in liver cancer tissues. Cell proliferation, survival and migration capacities were determined by MTT, colony formation and wound‑healing assays, respectively. The targeting of high mobility group AT‑hook 2 (HMGA2) mRNA by miR‑363‑3p was confirmed by bioinformatics analysis, and RT‑qPCR, luciferase reporter and western blot assays. The correlation between the expression levels of HMGA2 and miR‑363‑3p was analyzed. The RT‑qPCR results revealed that the levels of miR‑363‑3p were downregulated in liver cancer tissues. Cellular assays validated that miR‑363‑3p exerted tumor suppressing functions, including the inhibition of cell proliferation, survival and migration abilities in two liver cancer cell lines. Bioinformatics prediction and subsequent experiments demonstrated that HMGA2 was a direct target of miR‑363‑3p. Restoration of the expression of HMGA2 in miR‑363‑3p mimic‑transfected cells reversed the tumor suppressing effects caused by miR‑363‑3p. Finally, there was a significant negative correlation between the expression levels of HMGA2 and miR‑363‑3p in liver cancer tissues. miR‑363‑3p was identified as an important tumor suppressor in liver cancer via targeting HMGA2, which may have potential benefits in liver cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.